Home Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission
Article
Licensed
Unlicensed Requires Authentication

Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission

  • Gergely Toldi EMAIL logo , Gabriella Bekő , Gabriella Kádár , Emília Mácsai , László Kovács , Barna Vásárhelyi and Attila Balog
Published/Copyright: June 21, 2012
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 51 Issue 2

Abstract

Background: Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker increasingly used for the assessment of systemic inflammation. We aimed to evaluate suPAR for the assessment of inflammatory activity in rheumatoid arthritis (RA) patients in remission.

Methods: In our cross-sectional study we measured plasma suPAR and C-reactive protein (CRP) levels as well as erythrocyte sedimentation rate (ESR) in 120 RA patients at various stages of disease activity and 29 healthy age-matched controls.

Results: suPAR, CRP and ESR values were higher in RA patients compared to healthy individuals. When suPAR levels were analyzed according to DAS28 scores of RA patients, suPAR level in the subgroup with DAS28≤2.6 was lower than in the subgroup with DAS28>2.6, but still higher than in controls [4.45 (3.33–5.56) ng/mL vs. 3.66 (3.10–4.67) ng/mL vs. 2.80 (2.06–3.42) ng/mL, p<0.0001, median (interquartile range)]. In contrast, CRP and ESR values were comparable in the subgroup with DAS28≤2.6 and in healthy individuals. We further analyzed the correlation between the number of tender and/or swollen joints and suPAR levels in RA patients in remission. suPAR values were significantly higher in patients with four tender and/or swollen joints than in patients with 2–3 or 0–1 tender and/or swollen joints.

Conclusions: While CRP and ESR values indicate remission of the chronic inflammatory process in RA, suPAR values are still elevated compared to healthy individuals. suPAR might be particularly valuable in the recognition of inflammatory activity in patients who are in remission according to DAS28 scores but have symptoms of tender and/or swollen joints.

Keywords: C-reactive protein (CRP); erythrocyte sedimentation rate (ESR); inflammation; rheumatoid arthritis; soluble urokinase plasminogen activator receptor (suPAR)
Corresponding author: Gergely Toldi, First Department of Pediatrics, Semmelweis University, Budapest, Bókay u. 53-54, 1083 Hungary Phone: +36 20 4367181, Fax: +36 1 3138212

This work was supported by the Hungarian Scientific Research Fund [OTKA; grant number 101661]; the Medical Research Council [grant number ETT 05-180/2009]; and a research grant from Roche Hungary Ltd.

Conflict of interest statement

Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. Research funding played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

References

1. Danø K, Behrendt N, Brünner N, Ellis V, Ploug M, Pyke C. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994;8: 189–203.10.1016/0268-9499(94)90717-XSearch in Google Scholar

2. Behrendt N, Stephens RW. The urokinase receptor. Fibrinolysis Proteol 1998;12:191–204.10.1016/S0268-9499(98)80013-1Search in Google Scholar

3. Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Høyer-Hansen G, Rønne E, et al. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997;43:1876–84.10.1093/clinchem/43.10.1868Search in Google Scholar

4. Rønne E, Pappot H, Grøndahl-Hansen J, Høyer-Hansen G, Plesner T, Hansen NE, et al. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995;89:576–81.10.1111/j.1365-2141.1995.tb08366.xSearch in Google Scholar PubMed

5. Ostergaard C, Benfield T, Lundgren JD, Eugen-Olsen J. Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis 2004;36:14–9.10.1080/00365540310017366Search in Google Scholar PubMed

6. Ostrowski SR, Ullum H, Goka BQ, Høyer-Hansen G, Obeng Adjei G, Pedersen BK, et al. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 2005;191:1331–41.10.1086/428854Search in Google Scholar PubMed

7. Balabanov R, Lisak D, Beaumont T, Lisak RP, Dore-Duffy P. Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1). Clin Diagn Lab Immunol 2001;8:1196–203.10.1128/CDLI.8.6.1196-1203.2001Search in Google Scholar PubMed PubMed Central

8. Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, et al. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998;58:1843–9.Search in Google Scholar PubMed

9. Toldi G, Bíró E, Szalay B, Stenczer B, Molvarec A, Rigó J Jr, et al. Soluble urokinase Plasminogen Activator Receptor (suPAR) levels in healthy pregnancy and preeclampsia. Clin Chem Lab Med 2011;49:1873–6.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000296772300016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed

10. Thunø M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009;27:157–72.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000271583500005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1155/2009/504294Search in Google Scholar PubMed

11. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954–60.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000266917100031&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1136/ard.2007.084459Search in Google Scholar PubMed PubMed Central

12. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81.10.1002/art.27584Search in Google Scholar PubMed

13. [No authors listed] ICSH recommendations for measurement of erythrocyte sedimentation rate. International Council for Standardization in Haematology (Expert Panel on Blood Rheology) J Clin Pathol 1993;46:198–203.10.1136/jcp.46.3.198Search in Google Scholar PubMed PubMed Central

14. Slot O, Brünner N, Locht H, Oxholm P, Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis 1999;58: 488–92.10.1136/ard.58.8.488Search in Google Scholar PubMed PubMed Central

15. Sier CF, Sidenius N, Mariani A, Aletti G, Agape V, Ferrari A, et al. Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest 1999;79:717–22.Search in Google Scholar PubMed

16. Riisbro R, Christensen IJ, Høgdall C, Brünner N, Høgdall E. Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers 2001;16:233–9.10.1177/172460080101600402Search in Google Scholar PubMed

17. Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission according to the disease activity score in 28 joints and is driven by residual swollen joints. Arthritis Rheum 2011;63:3702–11.10.1002/art.30634Search in Google Scholar PubMed

Received: 2012-04-04
Accepted: 2012-05-20
Published Online: 2012-06-21
Published in Print: 2013-02-01

©2013 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Letters to the Editor
  2. Performance evaluation of three different immunoassays for detection of antibodies to hepatitis B core
  3. Serum homocysteine concentrations in Chinese children with autism
  4. Interchangeability of venous and capillary HbA1c results is affected by oxidative stress
  5. Interference of hemoglobin (Hb) N-Baltimore on measurement of HbA1c using the HA-8160 HPLC method
  6. First human isolate of Mycobacterium madagascariense in the sputum of a patient with tracheobronchitis
  7. Protein S and protein C measurements should not be undertaken during vitamin K antagonist therapy
  8. α2-HS glycoprotein is an essential component of cryoglobulin associated with chronic hepatitis C
  9. An unusual interference in CK MB assay caused by a macro enzyme creatine phosphokinase (CK) type 2 in HIV-infected patients
  10. An automated technique for the measurement of the plasma glutathione reductase activity and determination of reference limits for a healthy population
  11. Is osteopontin stable in plasma and serum?
  12. Evidence-based approach to reducing perceived wasteful practices in laboratory medicine
  13. Masthead
  14. Masthead
  15. Editorials
  16. Testing volume is not synonymous of cost, value and efficacy in laboratory diagnostics
  17. Lessons from controversy: biomarkers evaluation
  18. Commercial immunoassays in biomarkers studies: researchers beware!1)
  19. Trials and tribulations in lupus anticoagulant testing
  20. Reviews
  21. Mass spectrometry: a revolution in clinical microbiology?
  22. Chronic Chagas disease: from basics to laboratory medicine
  23. General Clinical Chemistry and Laboratory Medicine
  24. Shop for quality or quantity? Volumes and costs in clinical laboratories
  25. Minor improvement of venous blood specimen collection practices in primary health care after a large-scale educational intervention
  26. Evaluation of high resolution gel β2-transferrin for detection of cerebrospinal fluid leak
  27. Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease
  28. Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission
  29. Bone mass density selectively correlates with serum markers of oxidative damage in post-menopausal women
  30. Validation of a fast and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) with atmospheric pressure chemical ionization method for simultaneous quantitation of voriconazole, itraconazole and its active metabolite hydroxyitraconazole in human plasma
  31. Performance of different screening methods for the determination of urinary glycosaminoclycans
  32. Intestinal permeability and fecal eosinophil-derived neurotoxin are the best diagnosis tools for digestive non-IgE-mediated cow’s milk allergy in toddlers
  33. An internal validation approach and quality control on hematopoietic chimerism testing after allogeneic hematopoietic cell transplantation
  34. Serum levels of IgG antibodies against oxidized LDL and atherogenic indices in HIV-1-infected patients treated with protease inhibitors
  35. Cooperation experience in a multicentre study to define the upper limits in a normal population for the diagnostic assessment of the functional lupus anticoagulant assays
  36. Contribution of procoagulant phospholipids, thrombomodulin activity and thrombin generation assays as prognostic factors in intensive care patients with septic and non-septic organ failure
  37. Suitability of POC lactate methods for fetal and perinatal lactate testing: considerations for accuracy, specificity and decision making criteria
  38. Point-of-care testing on admission to the intensive care unit: lactate and glucose independently predict mortality
  39. Reference Values and Biological Variations
  40. CA125 reference values change in male and postmenopausal female subjects
  41. Distributions and ranges of values of blood and urinary biomarker of inflammation and oxidative stress in the workers engaged in office machine manufactures: evaluation of reference values
  42. Cancer Diagnostics
  43. Association of acute phase protein-haptoglobin, and epithelial-mesenchymal transition in buccal cancer: a preliminary report
  44. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients
  45. Evaluation of the BRAHMS Kryptor® Thyroglobulin Minirecovery Test in patients with differentiated thyroid carcinoma
https://doi.org/10.1515/cclm-2012-0221
Keywords for this article
C-reactive protein (CRP); erythrocyte sedimentation rate (ESR); inflammation; rheumatoid arthritis; soluble urokinase plasminogen activator receptor (suPAR)

Articles in the same Issue

  1. Letters to the Editor
  2. Performance evaluation of three different immunoassays for detection of antibodies to hepatitis B core
  3. Serum homocysteine concentrations in Chinese children with autism
  4. Interchangeability of venous and capillary HbA1c results is affected by oxidative stress
  5. Interference of hemoglobin (Hb) N-Baltimore on measurement of HbA1c using the HA-8160 HPLC method
  6. First human isolate of Mycobacterium madagascariense in the sputum of a patient with tracheobronchitis
  7. Protein S and protein C measurements should not be undertaken during vitamin K antagonist therapy
  8. α2-HS glycoprotein is an essential component of cryoglobulin associated with chronic hepatitis C
  9. An unusual interference in CK MB assay caused by a macro enzyme creatine phosphokinase (CK) type 2 in HIV-infected patients
  10. An automated technique for the measurement of the plasma glutathione reductase activity and determination of reference limits for a healthy population
  11. Is osteopontin stable in plasma and serum?
  12. Evidence-based approach to reducing perceived wasteful practices in laboratory medicine
  13. Masthead
  14. Masthead
  15. Editorials
  16. Testing volume is not synonymous of cost, value and efficacy in laboratory diagnostics
  17. Lessons from controversy: biomarkers evaluation
  18. Commercial immunoassays in biomarkers studies: researchers beware!1)
  19. Trials and tribulations in lupus anticoagulant testing
  20. Reviews
  21. Mass spectrometry: a revolution in clinical microbiology?
  22. Chronic Chagas disease: from basics to laboratory medicine
  23. General Clinical Chemistry and Laboratory Medicine
  24. Shop for quality or quantity? Volumes and costs in clinical laboratories
  25. Minor improvement of venous blood specimen collection practices in primary health care after a large-scale educational intervention
  26. Evaluation of high resolution gel β2-transferrin for detection of cerebrospinal fluid leak
  27. Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease
  28. Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission
  29. Bone mass density selectively correlates with serum markers of oxidative damage in post-menopausal women
  30. Validation of a fast and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) with atmospheric pressure chemical ionization method for simultaneous quantitation of voriconazole, itraconazole and its active metabolite hydroxyitraconazole in human plasma
  31. Performance of different screening methods for the determination of urinary glycosaminoclycans
  32. Intestinal permeability and fecal eosinophil-derived neurotoxin are the best diagnosis tools for digestive non-IgE-mediated cow’s milk allergy in toddlers
  33. An internal validation approach and quality control on hematopoietic chimerism testing after allogeneic hematopoietic cell transplantation
  34. Serum levels of IgG antibodies against oxidized LDL and atherogenic indices in HIV-1-infected patients treated with protease inhibitors
  35. Cooperation experience in a multicentre study to define the upper limits in a normal population for the diagnostic assessment of the functional lupus anticoagulant assays
  36. Contribution of procoagulant phospholipids, thrombomodulin activity and thrombin generation assays as prognostic factors in intensive care patients with septic and non-septic organ failure
  37. Suitability of POC lactate methods for fetal and perinatal lactate testing: considerations for accuracy, specificity and decision making criteria
  38. Point-of-care testing on admission to the intensive care unit: lactate and glucose independently predict mortality
  39. Reference Values and Biological Variations
  40. CA125 reference values change in male and postmenopausal female subjects
  41. Distributions and ranges of values of blood and urinary biomarker of inflammation and oxidative stress in the workers engaged in office machine manufactures: evaluation of reference values
  42. Cancer Diagnostics
  43. Association of acute phase protein-haptoglobin, and epithelial-mesenchymal transition in buccal cancer: a preliminary report
  44. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients
  45. Evaluation of the BRAHMS Kryptor® Thyroglobulin Minirecovery Test in patients with differentiated thyroid carcinoma
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 16.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2012-0221/html?lang=en
Scroll to top button